Authors: Sharon Salt
Results from an international trial have demonstrated that hematopoietic stem cell transplantation (HSCT) is an effective and safe treatment for patients with relapsing multiple sclerosis (MS).
The MIST trial demonstrated that HSCT can stabilize relapsing MS and improve disability in individuals who were still experiencing relapses while taking other disease-modifying therapies (DMTs).
To view restricted content, please:
